Buy Atarax (Hydroxyzine) Online — Versatile Antihistamine for Allergy, Chronic Itching & Anxiety

• Active ingredient: hydroxyzine hydrochloride
• Drug class: first-generation H1 antihistamine with anxiolytic properties
• FDA approved: 1956 (Atarax); 1958 (Vistaril pamoate salt)
• Available forms: tablets (10, 25, 50, 100 mg), syrup (10 mg/5 mL), injection (25, 50 mg/mL)
• Onset: typically 15–30 minutes (faster than newer antihistamines)
• Half-life: approximately 20 hours in adults
• Generic: widely available and inexpensive
• Active metabolite: cetirizine (the active ingredient in Zyrtec)

1. H1 histamine receptor blockade (primary mechanism)
Hydroxyzine binds tightly to H1 histamine receptors throughout the body. This blocks the histamine-mediated symptoms of allergy: itching, vasodilation (hives, swelling), increased vascular permeability, and sensory nerve activation. The H1 antihistamine effect explains its use in urticaria, pruritus, and allergic conditions.

2. 5-HT2A serotonin receptor antagonism (anxiolytic mechanism)
Hydroxyzine blocks 5-HT2A serotonin receptors — the same receptors targeted by some modern anxiolytics and antipsychotics. This contributes to its anxiolytic effect, calming brain regions involved in anxiety processing. Unlike benzodiazepines which act on GABA-A receptors, hydroxyzine produces anxiolysis through this different pathway.

3. Alpha-1 adrenergic receptor blockade
Hydroxyzine has moderate alpha-1 receptor blocking effect, contributing to its calming and sedative properties. This also explains some of its side effects: dizziness on standing (orthostatic hypotension), particularly in elderly patients.

4. Muscarinic acetylcholine receptor blockade (anticholinergic effects)
Hydroxyzine moderately blocks muscarinic acetylcholine receptors, explaining its anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention. This anticholinergic burden is one of the main reasons hydroxyzine is problematic in elderly patients.

5. D2 dopamine receptor mild antagonism
Hydroxyzine has weak D2 dopamine blocking effect, contributing to its antiemetic action and mild psychomotor effects. This effect is much milder than antipsychotics or metoclopramide.

• Hydroxyzine is metabolised by the liver, primarily to cetirizine
• Cetirizine is the active ingredient in Zyrtec
• This means: take Atarax = your body also produces Zyrtec effects
• Cetirizine does NOT cross the blood-brain barrier as readily as hydroxyzine
• So while you produce cetirizine, you also retain the original hydroxyzine effects (especially CNS)
• This dual presence may explain hydroxyzine sustained effects
• Half-life: hydroxyzine ~20 hours; cetirizine ~8 hours

• No dependence develops with hydroxyzine, even with daily use
• No withdrawal syndrome when stopped after long-term use
• No tolerance to anxiolytic effect (does not lose effectiveness over time)
• No abuse potential — not a controlled substance
• No black-box warnings like benzodiazepines
• Can be used in patients with substance use history

• For allergy alone: newer non-sedating antihistamines are first-line because no sedation
• For chronic anxiety alone: SSRIs are first-line because more effective long-term
• Hydroxyzine shines when both conditions coexist, or when alternatives are contraindicated

• Synthesised at UCB Pharma in Belgium in 1955
• Original goal: create newer antihistamines after the success of diphenhydramine (1946)
• Initial trials showed both antihistamine AND unexpected anxiolytic effects
• The anxiolytic effect was not understood at the time but clinically remarkable
• Approved as both an antihistamine and anxiolytic - unusual dual approval
• Marketed as Atarax (HCl salt) in 1956; Vistaril (pamoate) added 1958

• Researchers discovered hydroxyzine is metabolised primarily to cetirizine
• Cetirizine retains H1 antihistamine activity
• Cetirizine does NOT cross the blood-brain barrier as readily
• So cetirizine has the antihistamine effect WITHOUT the sedation
• UCB Pharma commercialised cetirizine as Zyrtec in the 1990s
• Zyrtec became a top-selling antihistamine globally
• Hydroxyzine effectively spawned its own competitor!

In March 2015, the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) reviewed hydroxyzine cardiac safety. Findings:

• QT prolongation risk requires attention
• New dosing limits: max 100 mg/day adults, 50 mg/day elderly
• Avoid in patients with QT prolongation risk factors
• Avoid combination with other QT-prolonging drugs
• Major product information updates

• Adults: 50–100 mg/day in 3–4 divided doses (e.g., 25 mg 4 times daily)
• Maximum: 100 mg/day (per 2015 EMA limit)
• Elderly: max 50 mg/day; start at lower dose (25 mg/day)
• Renal/hepatic impairment: dose reduction
• Acute anxiety: 25–50 mg as single dose can be effective
• Onset: 30–60 minutes
• Duration: 4–6 hours per dose; sustained with regular dosing

• No tolerance — effect does not diminish with regular use
• No physical dependence — can stop without withdrawal
• No abuse potential — not a controlled substance
• No respiratory depression — safer in overdose
• Compatible with substance recovery
• No "rebound anxiety" when stopping
• No memory or cognitive impairment like benzodiazepines

• Problem: SSRIs take 4–6 weeks for full anxiolytic effect
• Solution: Use hydroxyzine for first 2–6 weeks while SSRI is working
• Approach: Start SSRI + hydroxyzine 25–50 mg 1–3x daily as needed
• Taper: Reduce hydroxyzine gradually as SSRI takes effect
• Outcome: Patient gets immediate relief without dependence risk

• SSRIs treat underlying mood/anxiety pathology more fundamentally
• SSRIs reduce relapse rates better with sustained use
• Hydroxyzine sedation can limit daily function
• QT considerations limit hydroxyzine in some patient populations
• Long-term cardiac safety of any QT-prolonging drug requires consideration

• Hives (wheals) — raised, red, itchy welts on skin
• Itching — often severe; the most distressing symptom
• Angioedema — swelling of deeper tissues (lips, eyelids, hands)
• Episodic appearance — lesions come and go over hours
• Often worse at night — intense itch disrupts sleep
• Often no identifiable trigger — "chronic spontaneous urticaria"
• Duration: by definition, lasting more than 6 weeks (often years)
• Quality of life impact: substantial, comparable to severe asthma

• Nocturnal breakthrough itch — even when daytime symptoms controlled, nighttime itch wakes patient; bedtime hydroxyzine often helps
• Antihistamine-resistant cases — some patients respond to first-gen when not to 2nd-gen
• Combined anxiety from urticaria — addresses both itch and distress
• Acute severe flare — rapid onset useful for sudden severe symptoms
• Add-on while waiting for biologic — bridge during 3-month onset of omalizumab
• Cost-effective option — generic widely available

• Adults: 25 mg 3–4 times daily, up to 100 mg/day
• Common practical regimen: 25 mg morning, 25 mg afternoon, 50 mg at bedtime (for nocturnal itch)
• For nighttime itch only: 25–50 mg at bedtime
• Add to existing 2nd-gen antihistamine — common modern approach
• Maximum: 100 mg/day (per EMA 2015 limit)
• Children: 0.5–1 mg/kg per dose; dose-titrated

• Brain H1 blockade — central component of itch perception
• 5-HT2A antagonism — serotonin contributes to itch in some patients
• Sedation — reduces awareness of itch, allows sleep
• Multi-receptor binding — broader effect than selective H1-only antagonists
• Anti-inflammatory effects — possibly through mast cell stabilisation

• Adults: 25 mg 3–4 times daily up to 100 mg/day total
• Common practical regimen: 25 mg morning + 25 mg afternoon + 50 mg bedtime
• For nighttime itch only: 25–50 mg at bedtime
• Children: 0.5–1 mg/kg per dose every 6 hours
• Elderly: 50 mg/day maximum; start at 25 mg/day
• Onset: 15–30 minutes
• Duration: 4–6 hours per dose

• Lying still in bed brings awareness of itch sensations
• Body temperature warming under blankets worsens many forms of itch
• Lack of distraction makes itch seem worse
• Scratching damages skin, perpetuating itch-scratch cycle
• Sleep loss worsens pain perception, mood, immune function
• Partner/family sleep also disrupted

• Anxiety increases perception of itch
• Chronic itch causes anxiety and depression
• Both involve serotonin and other neurotransmitters
• Stress hormones (cortisol) can worsen many skin conditions
• Sleep loss from either worsens the other
• Hydroxyzine's dual mechanism (antihistamine + anxiolytic) addresses both

• Anxiolysis — calms patient anxiety about the procedure
• Sedation — relaxes patient before anesthesia induction
• Antiemetic effect — reduces post-operative nausea and vomiting risk
• Antihistamine coverage — reduces allergic reactions to surgical materials
• Opioid sparing — reduces opioid needed during procedure
• Analgesic potentiation — enhances pain control of other medications

• Direct analgesic effect — hydroxyzine has mild analgesic properties
• Synergistic with opioids — potentiates pain relief
• Reduces opioid-induced nausea — allowing opioid tolerance
• Reduces anxiety component of pain — pain feels worse when anxious
• Improves sleep — better sleep reduces post-op pain perception
• Result: studies show 30–50% reduction in opioid requirements when hydroxyzine is part of regimen

• Adults: 25–50 mg every 4–6 hours as needed for anxiety, nausea, sleep, or opioid sparing
• Maximum: 100 mg/day per EMA limit
• Frequency reduces as patient recovers
• Stop within 1–2 weeks typically; not for long-term post-op use

• Direct sedation from H1 antihistamine effect on brain
• Anxiolytic effect — reduces racing thoughts that prevent sleep
• Reduced sleep latency — faster time to fall asleep
• Some effect on sleep maintenance — though shorter than dedicated hypnotics
• Reduced nocturnal itch — useful for pruritus-related sleep issues
• NOT REM-suppressing like some hypnotics — more natural sleep architecture

• Anxiety contributes to insomnia — the dual mechanism helps
• Pruritus causes nocturnal wakening — addresses both
• Substance use history — non-addictive
• Pregnancy — safer than many sleep aids in second/third trimester
• Failed melatonin, sleep hygiene — need stronger but non-addictive option
• Patient prefers non-controlled substance

• Consistent sleep schedule — same bedtime and wake time
• Bedroom for sleep only — not work, screens, or eating
• Cool, dark, quiet — optimal sleep environment
• No caffeine after 2 PM
• No alcohol in evening (disrupts sleep)
• No screens 1 hour before bed
• Light exercise during day
• Wind-down routine 30 min before bed
• Manage stress sources — not just sleep

• No tolerance to sedation — effect does not diminish with regular use
• No physical dependence — can stop without withdrawal insomnia
• No "rebound insomnia" — sleep returns to baseline when stopped
• Can be used PRN — only when needed, without dependence concerns
• Safe for relatively long-term use if needed, with monitoring

In 2015, the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) reviewed hydroxyzine cardiac safety and established maximum daily doses to reduce QT prolongation risk:

• Adults: maximum 100 mg per day (or 2 mg/kg/day, whichever lower)
• Elderly: maximum 50 mg per day
• Pediatric: 2 mg/kg/day (max varies by weight)
• Higher previous limits (200 mg/day or more) no longer recommended
• Most modern FDA labeling reflects similar concerns

• "Front-loading" at bedtime: common pattern: 25 mg morning + 25 mg afternoon + 50 mg bedtime for combined anxiety/itch
• "As needed" (PRN): common for acute anxiety: 25–50 mg as single dose
• "Bedtime-only": for sleep onset issues: 25–50 mg 30 min before bed
• Start at lower dose and titrate up based on response and sedation
• Tablet halving: 50 mg tablets can be halved for 25 mg dosing
• Syrup is bitter: may be mixed with juice or milk for children

• Anchor to meals — breakfast/lunch/dinner/bedtime is easier than arbitrary times
• Phone alarms — particularly if you skip meals
• Pill organiser — visible reminder of dose tracking
• Carry doses with you — small pill case for work/away from home
• Discuss with prescriber if consistent dosing is difficult — sometimes 2x daily acceptable

• Empty stomach — absorbs faster than with food
• Tablet vs syrup — syrup absorbs slightly faster
• IM injection — faster than oral (~30 min); used pre-op
• Higher dose — not faster onset, but stronger peak effect
• Age — elderly may have slower onset due to absorption changes
• Anxiety state — very anxious patients may not feel effects as quickly (perception)
• Concurrent medications — some affect liver metabolism, indirectly affecting onset of metabolites

• First dose: rapid onset; effect peaks 1–2 hours; decline by 4–6 hours
• Subsequent doses: build on residual from previous (long half-life)
• Steady state reached after 3–5 days of regular dosing
• At steady state: more sustained effect; less peak-trough variation
• For urticaria/pruritus: full benefit may take a week of consistent use
• For acute anxiety: single dose effect is what matters

• Available strengths: 10 mg, 25 mg, 50 mg, 100 mg
• Most common form for adults
• Score lines on some tablets allow halving for dose adjustment
• Generic versions widely available; identical efficacy
• Storage at room temperature; very stable
• Shelf life typically 2–3 years
• Cost: very inexpensive ($5–15 for monthly supply)

• Concentration: 10 mg per 5 mL (2 mg/mL)
• Primary use: pediatric dosing; elderly with swallowing difficulty
• Easier dose adjustment for small doses or weight-based pediatric
• Sugar or sweetener base (varies by brand); somewhat bitter aftertaste
• Storage at room temperature
• Shelf life typically 18 months after opening
• Cost: slightly more than tablets per dose
• Dosing accuracy requires syringe or measuring cup, not household spoon

• Concentrations: 25 mg/mL, 50 mg/mL
• Route: ONLY intramuscular — never IV (IV causes severe tissue damage and hemolysis)
• Primary uses: pre-operative sedation; agitation in hospital; patients unable to swallow
• Onset: 15–30 minutes (similar to oral, slightly faster)
• Administration: deep IM into large muscle (gluteal in adults; vastus lateralis in children)
• Pain at injection site common; can be substantial
• Tissue irritation with repeated injections
• Usually short-term (1–3 days); transition to oral as soon as possible

• Calculate by weight: 0.5–1 mg/kg per dose every 6 hours
• Example: 20 kg child needing 0.5 mg/kg per dose = 10 mg per dose
• Volume calculation: 10 mg = 5 mL of syrup (using 10 mg/5 mL concentration)
• Use oral syringe, not kitchen spoon, for accuracy
• Mix with small amount of juice if child refuses pure syrup
• Do not mix with full bottle — child may not finish

Hydroxyzine should NEVER be given intravenously (IV). Even accidental IV administration can cause:

• Severe tissue damage and necrosis at the IV site
• Hemolysis (red blood cell destruction)
• Severe injection-site reactions
• Compartment syndrome in extremities
• Possible amputation in severe cases (rare but documented)

• Same active drug: hydroxyzine
• Same mechanism: H1 antihistamine, 5-HT2A antagonist, alpha-1 blocker, muscarinic blocker
• Same indications: anxiety, urticaria, pruritus, pre-op sedation
• Same active metabolite: cetirizine (Zyrtec)
• Same half-life: ~20 hours
• Same maximum daily dose: 100 mg for adults per 2015 EMA
• Same side effect profile
• Same drug interactions
• Same contraindications

• Atarax (HCl) launched in 1956; marketed broadly for allergy and anxiety
• Vistaril (pamoate) launched in 1958; marketed specifically for anxiety, with capsule form
• This positioning was a marketing decision, not a pharmacological one
• Today, both are used for any of the approved indications
• Prescriber choice often depends on familiarity, available formulation, insurance coverage

• "Hydroxyzine" on a prescription typically dispensed as generic HCl tablets
• Generic equivalents to both Atarax and Vistaril are widely available
• Pharmacist may substitute generic for brand unless prescriber specifies "DAW" (dispense as written)
• Cost: generic is much cheaper; insurance preference
• Functional equivalence: generic and brand provide same hydroxyzine effect

• Atarax tablets: Most commonly prescribed; widely available; cheap; multiple strengths
• Vistaril capsules: Slightly different feel; reportedly less bitter; common in psychiatric settings
• Choose based on: insurance coverage, prescriber preference, formulation needs, taste tolerance
• Clinical effect: essentially identical

• Drowsiness / sedation: the most common; affects 30–50% of patients; often the desired effect; may decrease with continued use
• Dry mouth: approximately 20% of patients; anticholinergic effect; usually mild
• Dizziness: approximately 10–15%; particularly on standing (orthostatic)
• Fatigue: related to sedation; may persist as "next-day grogginess"
• Headache: approximately 10%; usually mild
• Blurred vision: anticholinergic effect; usually mild and transient
• Constipation: anticholinergic effect; manageable with diet and hydration
• Slight tremor: uncommon but possible
• Bitter aftertaste: from oral formulation

• Severe allergic reaction - facial swelling, breathing difficulty, hives
• Irregular or rapid heartbeat with dizziness
• Loss of consciousness or near-fainting
• Severe confusion, hallucinations, or delirium
• Widespread skin reaction with blistering
• Severe ongoing urinary retention (cannot urinate)
• New seizures

• Heavy eyelids — want to close eyes; lower lid pressure
• Slower mental tempo — thoughts feel less rushed
• Calm sleepiness — different from anxious tiredness
• Reduced startle response — calm to environmental triggers
• Decreased alertness — takes longer to notice things
• Cognitive slowing — less sharp; mild memory effects
• Coordination preserved mostly — not "drunk"
• No euphoria — mood remains your own

• Shift dose to evening — take larger dose at bedtime, smaller during day
• Reduce dose — sometimes 25 mg works almost as well as 50 mg with much less sedation
• Allow tolerance time — sedation often improves over 1–2 weeks
• Caffeine in morning — safely combined; offsets residual sedation
• Coordinate exercise — physical activity can offset sedation
• Avoid sedating combinations — alcohol, sleep aids, opioids
• Switch to less-sedating alternative — cetirizine, fexofenadine for allergy; SSRI for anxiety

• FDA-mandated warning: avoid activities requiring alertness
• Assess individual response in first 1–2 weeks before driving
• Pilots and commercial drivers often grounded on hydroxyzine
• Many countries classify sedating antihistamines as driving impairment risk
• Time of day matters: safer if last dose was many hours ago
• Combined with alcohol or other sedatives: dangerous; never drive

• Most patients develop tolerance to sedation over 1–2 weeks of regular use
• Anxiolytic and antihistamine effects are preserved despite tolerance to sedation
• Tolerance is not the same as physical dependence — no withdrawal syndrome
• Stop and restart: tolerance is lost over a few days off; sedation returns initially
• Patients who initially could not tolerate often do well after this adaptation period

• Acetylcholine — a neurotransmitter throughout the body
• It controls "rest and digest" functions: saliva, tears, digestion, urination
• It also affects brain function: memory, attention, alertness
• Anticholinergic drugs block these effects
• Result: drier mucous membranes, slower gut, harder urination, possible cognitive effects
• Many medications have anticholinergic effects, often combining additively

• Drink water frequently — small sips throughout day
• Sugar-free gum or candy — stimulates saliva
• Saliva substitutes (Biotene, OraCoat) — for severe cases
• Lip balm — lips also affected
• Mouth rinses — alcohol-free types
• Humidifier at bedtime — reduces overnight oral dryness
• Watch for tooth decay — dry mouth increases risk
• Dental check-ups — particularly for long-term users

• Increase fluid intake — 8 glasses of water daily
• Increase fiber — fruits, vegetables, whole grains
• Physical activity — even walking helps
• Stool softeners (docusate) — if dietary measures insufficient
• Avoid stronger laxatives long-term if possible
• Address with prescriber if severe; dose reduction may help

• Patients with BPH (benign prostatic hyperplasia) are at highest risk
• Symptoms: difficulty starting stream, weak stream, dribbling, incomplete emptying
• Severe retention: cannot urinate; bladder distention; medical emergency
• Discuss BPH history with prescriber before starting
• Caution in other conditions: prostate issues, neurogenic bladder
• If retention develops: report immediately; dose reduction or discontinuation may be needed

• Hydroxyzine score: 2-3 on most anticholinergic burden scales (moderate)
• Strongest anticholinergic medications (score 3): hydroxyzine, diphenhydramine, oxybutynin, amitriptyline
• Cumulative burden from multiple medications increases risk
• Older adults with score > 3 on multiple medications: significantly elevated dementia risk
• This is why hydroxyzine is flagged in elderly patients

• You are over 65 (Beers criteria flag)
• You take multiple anticholinergic medications
• You have memory or cognitive concerns
• You have BPH or prostate issues
• You have glaucoma (closed-angle)
• You have severe GI motility problems
• You have autonomic neuropathy

• Known hypersensitivity to hydroxyzine or its metabolites (cetirizine, levocetirizine)
• Hypersensitivity to piperazine derivatives or aminophylline (chemical relatives)
• QT prolongation — congenital long QT syndrome or significant acquired QT prolongation
• Concurrent use of QT-prolonging medications in those at risk
• Significant electrolyte abnormalities — low potassium, magnesium
• Significant bradycardia (slow heart rate)
• Severe heart failure or recent heart attack
• Early pregnancy (first trimester) — per EMA recommendation; later pregnancy with caution
• Porphyria — can trigger acute porphyria episodes
• Intravenous administration — never IV; tissue damage

• Age over 65 — Beers criteria flagged; 50 mg/day max per EMA
• Closed-angle glaucoma — anticholinergic effect can worsen
• BPH / urinary retention history — anticholinergic effect
• Severe constipation or paralytic ileus
• Myasthenia gravis
• Severe liver impairment — affects metabolism
• Severe renal impairment — CrCl < 50
• Dementia or cognitive impairment — anticholinergic burden
• Falls risk — particularly in elderly
• Driving / operating machinery — assess sedation
• History of substance abuse — though hydroxyzine is non-addictive, monitor carefully
• Concurrent use of multiple anticholinergic medications
• Hyperthyroidism — rare but increased sensitivity
• Asthma — secretions thickening may worsen

• Second/third trimester pregnancy — discussed in dedicated section
• Breastfeeding — minimal data; usually acceptable
• Children — weight-based dosing
• Mild liver disease — standard dose with monitoring
• Mild renal disease — standard dose with monitoring
• Diabetes — no concern
• Hypertension — no specific concern (some BP-lowering effect possible)
• Depression — not contraindicated; may even help anxiety component
• Substance recovery — non-addictive option (advantage here)

• Complete medication list including OTC and supplements
• Cardiac history — particularly any rhythm problems, fainting
• Family history of sudden cardiac death
• Pregnancy status or planning
• Breastfeeding
• Liver or kidney disease
• Urinary symptoms
• Eye problems including glaucoma
• Cognitive concerns
• Alcohol use patterns
• Driving/safety-critical job
• Falls history in elderly
• Allergies to other medications

The European Medicines Agency PRAC review in 2015 advised:

• Avoid hydroxyzine in early pregnancy (first trimester)
• Use cautiously in later pregnancy if alternatives inadequate
• Avoid near term if possible due to neonatal effects
• FDA Pregnancy Category C (older classification) — animal studies show some effects

• Animal studies showed some teratogenic effects at high doses
• Human data from decades of use without clear birth defect pattern
• First trimester exposure has theoretical concerns but human data is reassuring
• Later pregnancy shows no clear pattern of harm
• Near delivery: hypotonia, withdrawal-like symptoms in newborn reported
• Long-term outcome studies in children exposed in utero generally reassuring

• Severe pregnancy-induced anxiety (second/third trimester) not controlled by therapy alone
• Severe pruritus in pregnancy (intrahepatic cholestasis of pregnancy, etc.)
• Severe urticaria not controlled by safer alternatives
• Insomnia related to anxiety or itch when other approaches fail
• Pre-cesarean delivery sedation (single dose)
• Acute severe anxiety requiring rapid relief

• Discuss hydroxyzine use with obstetrician before conception
• Consider switching to safer alternative proactively (cetirizine, SSRI if needed)
• If on hydroxyzine when pregnancy occurs, do not stop abruptly — discuss with prescriber
• Adjust timing of dose to avoid first-trimester exposure if possible
• Document for healthcare team

• Excretes into breast milk in small amounts
• Active metabolite cetirizine also in milk
• Generally considered compatible with breastfeeding
• Watch infant for sedation — particularly newborns and premature infants
• Higher doses require more monitoring
• Lactation specialists often recommend cetirizine or loratadine when newer antihistamines acceptable
• Single-dose use for acute anxiety usually fine
• Long-term daily use requires more careful infant monitoring

• Intrahepatic cholestasis of pregnancy (ICP) — severe itch, particularly palms and soles; requires specialist management
• Polymorphic eruption of pregnancy (PEP) — itchy rash in third trimester
• Pemphigoid gestationis — rare autoimmune skin condition
• Simple pruritus gravidarum — idiopathic itching
• Hydroxyzine sometimes used for severe pregnancy itch when topical treatment insufficient
• Maternal benefit (sleep, comfort) usually justifies risk in 2nd/3rd trimester use

• Standard dose: 0.5–1 mg/kg per dose every 6 hours
• 2015 EMA limit: maximum 2 mg/kg/day (or 50 mg/day for under-6, whichever lower)
• Children under 6: max 50 mg/day total
• Children 6–12: max 50–100 mg/day depending on weight
• Adolescents 12+: adult dosing applies (max 100 mg/day)

• Atopic dermatitis with severe nocturnal itch — bedtime dose allows sleep
• Acute hives — particularly when first-gen antihistamine response is good
• Insect bite reactions — severe itching
• Pre-operative anxiety — better tolerated than alternatives
• Acute anxiety in medical settings — needle phobia, procedures
• Chicken pox itch — severe nocturnal symptoms
• Drug-induced rash with itch

• SSRIs (sertraline, fluoxetine) are first-line for childhood anxiety disorders
• Cognitive-behavioral therapy (CBT) highly effective in children
• Hydroxyzine useful for acute or situational anxiety, not chronic GAD
• Benzodiazepines generally avoided in children
• Buspirone sometimes used
• Discuss treatment options with child psychiatrist

• Use oral syringe for syrup, not kitchen spoon (accuracy)
• Refrigerate after first opening if needed for taste
• Mix with small amount of juice if child refuses pure syrup
• Bedtime dose particularly useful for nocturnal itch
• Set alarm for next dose to maintain schedule
• Watch for sedation affecting school the next day
• Inform school if child takes morning dose (drowsiness)
• Communicate with prescriber about effectiveness and side effects

• The American Geriatrics Society publishes the Beers Criteria
• Lists medications considered potentially inappropriate in older adults
• Based on evidence of harm or increased risk in elderly
• Updated periodically (most recent: 2023 update)
• Used by geriatricians, primary care, pharmacists, regulators
• Flag is not absolute — medication can still be used when benefits clearly outweigh risks
• Often triggers prescription review and discussion

First-generation antihistamines including hydroxyzine: "Avoid; highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects."

This is a strong recommendation against use, though not absolute.

• Severe acute anxiety requiring rapid relief when alternatives inadequate
• Severe nocturnal itch from chronic urticaria when sleep is debilitatingly disrupted
• Pre-operative sedation (single dose; benefits clear)
• End-of-life care — comfort care, less stringent guidelines
• Other alternatives clearly inadequate — need documented rationale
• Short-term use (1–2 weeks) with monitoring
• Specialist supervision — particularly geriatrician or psychiatrist

• Maximum 50 mg/day for adults over 65
• Start at 10–25 mg to assess tolerance
• Slow titration if increasing
• Monitor cognitive function at each dose change
• Monitor for falls
• Monitor for orthostatic changes
• Reassess regularly — can it be reduced or stopped?

• Document rationale — why alternative options are inadequate
• Use minimum effective dose — rarely above 25 mg twice daily
• Periodic reassessment — can it be stopped or reduced?
• Cognitive monitoring — baseline and periodic
• Falls prevention — home environment safety
• Family involvement — family aware of risks
• Specialist input — geriatric medicine, psychiatry, pharmacy

• The QT interval is a measurement on an electrocardiogram (ECG)
• It represents the time the heart's electrical system takes to reset between beats
• Normal QT (corrected for heart rate): 350–440 milliseconds typically
• QT prolongation: longer than normal, indicating slower electrical recovery
• Significant prolongation (> 500 ms) can trigger dangerous arrhythmia
• The specific arrhythmia is torsades de pointes — a polymorphic ventricular tachycardia
• Can degenerate to ventricular fibrillation and sudden cardiac death

• Population-level data showed measurable QT prolongation at higher doses
• Rare cases of torsades de pointes reported in pharmacovigilance
• Risk concentrated in patients with multiple QT risk factors
• Conclusion: keep medication available but with dosing limits and clearer contraindications
• New recommendations issued in March 2015

• Congenital long QT syndrome — absolute contraindication
• Female sex — slightly higher risk
• Age > 65
• Hypokalemia (low potassium)
• Hypomagnesemia (low magnesium)
• Bradycardia (slow heart rate)
• Heart failure
• Recent heart attack
• Cardiac structural abnormalities
• Family history of sudden cardiac death
• Use of other QT-prolonging drugs
• Liver disease (affects metabolism)
• Renal disease (affects elimination)

• Palpitations — awareness of irregular or rapid heartbeat
• Lightheadedness or near-fainting
• Syncope — actually fainting
• Sudden severe weakness
• Chest discomfort with palpitations
• Sudden cardiac arrest — rare but serious

• The vast majority of hydroxyzine users have no cardiac issues
• The 2015 limits are precautionary — following them reduces risk substantially
• Combination with other QT drugs is the main practical concern
• Healthy adults at standard doses can use hydroxyzine safely
• The medication remains widely used globally for good reason — benefits clearly outweigh risks in appropriate patients

• Both alcohol and hydroxyzine sedate the brain through overlapping pathways
• Combined sedation is greater than the sum of each alone
• Reaction time impairment is more pronounced
• Cognitive function (memory, judgement) more affected
• Coordination and balance worsen significantly
• Falls risk increases substantially
• Driving impairment becomes serious
• Respiratory depression possible at high combined doses (rare)
• Risk of accidents, injuries, and dangerous behaviour

• Cannot stay awake - falling asleep at inappropriate times
• Severe confusion or disorientation
• Slurred speech beyond normal alcohol effect
• Difficulty walking - severe coordination loss
• Slow or shallow breathing
• Unresponsiveness
• Skin appears bluish (cyanosis)
• Unconsciousness

• "Glass of wine at dinner": Generally acceptable if dose was earlier in day; do not drive after
• "Beer with friends Friday night": Skip or significantly reduce hydroxyzine that day
• "Wedding/event with drinking": Consider holding hydroxyzine the day of event
• "Daily glass before bed": Not advisable; combination causes morning grogginess
• "Hangover anxiety": Hydroxyzine helps but combination with residual alcohol still risky
• "Sobriety in recovery": Ideal — hydroxyzine is safe choice for anxiety

• The FDA warning on hydroxyzine includes driving precaution
• Combined with alcohol, this becomes critical
• Legal alcohol limits still apply, but impairment occurs at lower levels
• Reaction time can be more than doubled
• "Buzzed driving" judgement is significantly worse
• Professional drivers should not combine
• Many countries have stricter rules for prescription sedatives + alcohol

• Not a controlled substance
• No dependence develops
• No abuse potential
• Safe for patients in alcohol or drug recovery
• Often preferred over benzodiazepines for this population
• Can be used during recovery without compromising sobriety

• Confidentiality protects you in medical care
• Allows prescriber to adjust medication choice
• Heavy drinking is itself a treatable condition
• Alternative anxiolytics may be more compatible
• Documenting patterns helps with comprehensive care

• SSRI provides long-term anxiolytic effect through serotonin pathways
• Hydroxyzine provides immediate anxiolytic effect for breakthrough symptoms
• SSRI bridge therapy: hydroxyzine covers first 4–6 weeks until SSRI works
• Once SSRI established: hydroxyzine can be tapered or used PRN only
• Both well-studied in this combination
• Watch combined QT effect if SSRI is citalopram or escitalopram at high doses

• Pre-operative sedation — midazolam + hydroxyzine common
• Alcohol withdrawal — benzo + hydroxyzine for agitation
• Severe acute anxiety — brief combined use
• During benzodiazepine taper — hydroxyzine as supportive
• Inpatient psychiatric care — specialist supervised

• Heavy combined sedation with most antipsychotics
• Additive QT prolongation with many antipsychotics
• Additive anticholinergic burden with olanzapine, clozapine, chlorpromazine
• Specialist supervision required for combinations
• Aripiprazole (Abilify) and ziprasidone lower antihistamine and sedation overlap
• Haloperidol has its own QT concerns; combination requires care

• ✅ Generally safe combination
• Both target anxiety through different mechanisms
• Buspirone non-sedating, hydroxyzine sedating — complementary
• Sometimes used together for complex anxiety presentations
• Specialist supervision useful

• Macrolide antibiotics: azithromycin, clarithromycin, erythromycin
• Fluoroquinolones: ciprofloxacin, levofloxacin, moxifloxacin
• Antiarrhythmics: amiodarone, sotalol, dofetilide, ibutilide
• Antipsychotics: haloperidol, ziprasidone, thioridazine, chlorpromazine
• Antiemetics: ondansetron, droperidol, prochlorperazine
• Methadone
• Some antifungals: ketoconazole, itraconazole
• Some HIV medications: certain protease inhibitors

• Cimetidine (Tagamet) — may increase hydroxyzine levels
• Some antifungals — ketoconazole, fluconazole
• Some antibiotics — erythromycin, clarithromycin
• Carbamazepine — may decrease effect
• Rifampin — may decrease effect
• St. John's wort — may decrease effect

• Cold and flu medications — often contain first-gen antihistamines; check labels carefully
• Sleep aids — Tylenol PM, Advil PM, Unisom contain antihistamines; avoid combining
• Motion sickness pills — additive sedation and anticholinergic effects
• Allergy combination products — may double-dose antihistamines
• Cough suppressants — some contain dextromethorphan; mild sedation possible
• Anti-anxiety supplements — valerian, kava, passionflower may add sedation
• Cannabis / CBD — can cause additive sedation

• Severe acute anxiety requiring immediate strong relief
• Panic disorder — benzos work well for panic attacks
• Status epilepticus — lorazepam, diazepam life-saving
• Alcohol withdrawal — cross-tolerance with alcohol; gold standard
• Severe agitation in psychiatric emergencies
• Acute manic episodes — calming effect
• Procedural sedation — conscious sedation
• Anesthesia induction — midazolam, lorazepam

• Substance use history — alcohol or drug recovery
• Need for non-addictive option
• Concurrent opioid use — FDA black box warning against benzos + opioids
• Elderly without dementia — safer than benzos in many ways
• Long-term use needed — no tolerance develops
• Pregnancy (2nd/3rd trimester) — better data than benzos
• Anxiety + insomnia + itch — treats multiple symptoms
• Patient prefers non-controlled substance
• Mild-to-moderate anxiety — benzos overkill

The FDA has issued a black box warning against combining benzodiazepines with opioids due to fatal respiratory depression risk. Hydroxyzine does NOT carry the same warning. This makes hydroxyzine significantly safer for patients on chronic opioid therapy who also need anxiety treatment.

• Hydroxyzine alone cannot prevent benzodiazepine withdrawal
• Gradual benzo taper over months while introducing hydroxyzine
• Specialist supervision recommended
• Hydroxyzine addresses anxiety as benzo decreases
• Watch for withdrawal symptoms — insomnia, anxiety rebound, seizure risk
• Consider SSRI as long-term foundation
• Psychotherapy is critical adjunct

• Hydroxyzine (Atarax) — the original molecule, FDA approved 1956
• Metabolised by liver primarily to cetirizine
• Cetirizine (Zyrtec) — the metabolite, marketed separately starting 1995
• Cetirizine does NOT cross the blood-brain barrier as readily as hydroxyzine
• So: cetirizine has the antihistamine effect WITHOUT the sedation
• Levocetirizine (Xyzal) — the active enantiomer of cetirizine; even more refined

• Less sedation — can maintain daily function
• Once-daily dosing — better adherence
• OTC availability — easier access
• Less anticholinergic burden — safer in elderly
• Comparable allergy effectiveness — at least as effective for most patients
• Lower interaction risk — cleaner drug profile

• Severe nocturnal itch — the sedation is desired
• Anxiety component — only hydroxyzine has this
• Antihistamine-resistant urticaria — sometimes works when newer fail
• Pre-operative use — combined sedation needed
• Sleep difficulty with itch — addresses both
• Combined with newer antihistamine — bedtime adjunct to daytime non-sedating

• Step 1: Cetirizine, fexofenadine, or loratadine standard dose daily
• Step 2: Up to 4x standard dose of same drug
• Add hydroxyzine at bedtime if nocturnal symptoms persist
• Step 3: Add omalizumab (anti-IgE biologic)
• Step 4: Cyclosporine or other immunosuppressant

• Chronic anxiety disorder requiring daily treatment for months/years
• Panic disorder — SSRIs treat the underlying disorder
• PTSD — SSRIs (sertraline, paroxetine) are first-line
• Social anxiety disorder
• Obsessive-compulsive disorder
• Depression with anxiety
• Anxiety in pregnancy — SSRI data more extensive
• Sedation cannot be tolerated — daily function important
• Want medication that "treats the disorder"

• Acute situational anxiety — needs immediate relief
• Pre-procedural anxiety — surgery, dental work
• Bridge therapy — first weeks while SSRI builds effect
• Breakthrough anxiety on SSRI — adjunct for occasional severe episodes
• Patient cannot tolerate SSRI side effects (sexual, weight, GI)
• Patient declines daily medication — preference for PRN approach
• Combined anxiety + insomnia or itch
• Short-term need — weeks not months

• Day 1: Start SSRI (low dose); start hydroxyzine PRN for breakthrough
• Week 1–2: SSRI building; hydroxyzine covers immediate symptoms
• Week 3–4: SSRI titrated; hydroxyzine still useful for breakthrough
• Week 4–6: SSRI taking full effect; hydroxyzine needed less often
• Month 2+: Hydroxyzine usually PRN only; SSRI maintains baseline control
• Outcome: Patient never experiences uncontrolled anxiety while waiting for SSRI

• Venlafaxine (Effexor) — FDA approved for GAD, panic, social anxiety
• Duloxetine (Cymbalta) — FDA approved for GAD
• Similar to SSRIs in effectiveness for anxiety
• Different side effect profile — sometimes less sexual side effects
• Hydroxyzine combines well with these too

• Active ingredient always listed: hydroxyzine hydrochloride or hydroxyzine pamoate
• Strength: 10 mg, 25 mg, 50 mg, 100 mg (consistent globally)
• ATC code: N05BB01 (used internationally)
• WHO INN (International Nonproprietary Name): hydroxyzine
• Common forms: tablet, syrup, capsule (Vistaril), injection

• Carry enough for entire trip plus extra week
• Pack in original packaging with prescription label
• Doctor letter stating diagnosis and medication need
• Carry in carry-on luggage — never checked baggage
• Know the brand name in destination country
• Translation of medication name in destination language
• Hydroxyzine is not a controlled substance in most countries (unlike benzos)
• Customs concerns are minimal for routine quantities

• Verify legitimate source — many online "pharmacies" sell counterfeits
• Look for proper licensing (LegitScript, NABP, or country equivalent)
• Beware extremely low prices — likely counterfeit
• Hydroxyzine is widely produced by reputable generic manufacturers globally
• UCB Pharma (Belgian) makes original Atarax brand
• Major Indian generic manufacturers produce quality versions
• Always carry prescription when importing
• Check legal status for personal importation in your country

• UCB Pharma (Union Chimique Belge) — Belgian pharmaceutical company
• Founded in 1928
• Original developer and patent holder of hydroxyzine
• Originally marketed Atarax globally
• Also discovered and commercialized cetirizine (Zyrtec) - the metabolite
• Today: still markets Atarax in many countries
• Most current Atarax is generic from other manufacturers

• If you remember within 1–2 hours of the missed dose time: take it immediately, continue normal schedule
• If more than 2 hours late but next dose is > 3 hours away: take now, continue schedule
• If next dose is within 3 hours: skip the missed dose, take next dose as scheduled
• Never double-dose to make up for a missed one

• No withdrawal syndrome — can stop abruptly without medical danger
• No rebound anxiety — underlying anxiety returns to baseline, not worse
• No rebound itch — underlying condition resumes
• No physical dependence — not addictive
• No taper needed — can stop and restart freely
• No discontinuation syndrome

• Forgetting because of scheduling? — phone alarms, link to routine
• Sedation makes adherence difficult? — discuss timing or dose reduction
• Symptoms improving so feels unnecessary? — discuss tapering with prescriber
• Side effects bothersome? — discuss alternatives
• Multiple dosing too complex? — simplify schedule
• Cost concerns? — generic versions very affordable

• No tolerance develops — medication remains effective
• No physical dependence — no addiction concerns
• No withdrawal syndrome — can stop without medical danger
• Generally well-tolerated over years in appropriate patients
• No major organ toxicity at standard doses
• Compatible with most chronic medications
• Well-characterised safety profile

• Can stop abruptly — unlike benzodiazepines or SSRIs
• No withdrawal symptoms
• Original condition returns — the only "rebound"
• Can be restarted at any time without re-titration
• Cognitive effects typically improve within days off medication
• Dry mouth and anticholinergic effects resolve within days

• Regular dental care — counter dry mouth effects
• Adequate hydration — ongoing
• Adequate fiber — counter constipation
• Regular exercise — helps mood, anxiety, sleep, bowel function
• Sleep hygiene — even on sedating medication
• Address underlying conditions — therapy for anxiety, allergen avoidance for urticaria
• Regular medical follow-up
• Periodic dental check-ups
• Eye exams — particularly if blurred vision concerns

• Take more than the prescribed dose hoping for stronger effect
• Combine heavily with alcohol or other CNS depressants
• Drive or operate machinery if you feel sedated
• Stop suddenly if it has been effective without discussing with prescriber
• Use someone else's prescription
• Take in early pregnancy (first trimester) without specialist guidance
• Combine with multiple QT-prolonging drugs without monitoring
• Continue if cognitive effects become problematic (particularly elderly)
• Ignore signs of urinary retention or significant constipation
• Inject IV (intramuscular only)
• Combine with multiple anticholinergic medications without considering burden
• Use long-term as monotherapy for chronic anxiety (SSRIs preferred)

• Bathrooms — humidity from showers degrades medication; surprisingly bad location
• Kitchen near stove — heat exposure
• Direct sunlight — UV affects tablet stability
• Cars in summer — extreme heat
• Above heat-producing appliances

• Bedroom drawer
• Kitchen cabinet away from stove
• Medicine cabinet in non-bathroom location
• Office drawer (if work environment)

• Before opening: store at room temperature
• After first opening: use within 3-6 months (check label)
• Refrigeration optional — may help taste; not required
• Mark opening date on bottle when first used
• Shake before each use
• Use measuring syringe for accurate dosing
• Children's syrup particularly important to track opening date

• Carry enough for trip + 1 extra week as backup
• Pack in carry-on luggage — never checked baggage (temperature extremes, loss risk)
• Original packaging with prescription label — for customs and replacement if lost
• Doctor letter for international travel — signed and dated
• Translation of medication name in destination language
• Time zone changes: hydroxyzine's long half-life is forgiving; shift gradually
• Cool bag for hot climates or summer travel
• Multiple bottles for long trips — spread across luggage
• Not a controlled substance — usually fewer customs concerns than benzos

• Pharmacy take-back program — first choice; safe and environmentally responsible
• DEA-authorised drug collection sites — periodic events in US
• Household trash — mixed with unpalatable substance (coffee grounds, kitty litter) in sealed container if take-back not available
• Do not flush down toilet or sink — environmental contamination
• Remove personal information from prescription label before disposal
• Syrup disposal — pour into absorbent material before discarding